Aurora in the Polish pharmacy: ten strains, eight of which are not supplied by anyone else

Who is Aurora and where does the raw material sold under this name come from?

Aurora is a Canadian company, Aurora Cannabis, based in Edmonton, Alberta. However, its Berlin subsidiary, Aurora Deutschland, formerly Pedanios, is listed on the Polish label, and it is the entity responsible for the raw material in the registry. The company does not conduct cultivation or manufacturing in Poland.

The Berlin company was established in 2015 under the name Pedanios and was engaged in the wholesale sale of medical cannabis in Germany. The Canadian owner took it over in 2017, and in August 2018, the name changed to Aurora Deutschland to carry the brand of the parent company. This ownership structure explains why a German entity is listed in Poland, even though the entire group is Canadian.

Its presence in our market is in the form of an entry in the register of pharmaceutical raw materials approved for trading, rather than a production facility or a commercial representation. In response to a parliamentary inquiry from December 2019, the Ministry of Health listed five cannabis raw materials registered at that time: four attributed to Aurora Deutschland and one to Canopy Growth Polska. This was reported by the pharmacy.pl service at the end of January 2020. All were intended for the preparation of prescription medications in pharmacies, not for dispensing as ready-made medicinal products.

We were unable to determine the origin of the plant material in the batches arriving in Poland. The group operates facilities in Canada and cultivation in Leuna in Saxony-Anhalt, and the registration entry indicates the responsible entity, not the plantation. The country of origin for a specific batch is recorded in the documentation of its release, which is not publicly accessible.

Which Aurora strains are available in Polish pharmacies?

Ten. In a list covering eighty-five cultivars present in Polish pharmacies, Aurora accounts for ten names, placing it fifth among sixteen producers. Eight of these names are not listed by any other supplier, so the disappearance of this company would remove them from the market at once.

In this comparison, there are two competitors. Pink Kush appears in pharmacies in eight registered positions from five manufacturers, while Ghost Train Haze is listed in two, from Aurora and S-LAB, whose entire output is described. in a separate discussion. The remaining eight names are listed exclusively under this one entity.

Exclusivity is not a badge of quality here, but a consequence of how the raw material enters the market. The registry entry pertains to a specific entity's product, not the strain itself, so the genetics circulating worldwide under a known name may not have a counterpart in a Polish pharmacy. When such an entity withdraws a product, the name disappears entirely from the list and cannot be replaced.

The leading terpenes are unevenly distributed in this top ten. Limonene leads in three entries, terpinolene and myrcene in two each, while nerolidol, caryophyllene, and pinene close the list with one each. We do not provide percentage shares for these names, and the reason is explained below, in the evidence section.

Why can the word Aurora in the pharmacy list be misleading?

Because it sometimes refers to the manufacturer and at other times is part of the strain name. In the Polish registry, the entry is called Cannabis flos Aurora Deutschland GmbH, and the word Aurora denotes the company. However, there is a cultivar called Aurora Indica, where the same word is part of the plant's name.

Aurora Indica originated from the breeding work of Nirvana Seeds and is a combination of Afghani and Northern Lights strains, described as nearly pure indica. There is nothing connecting it to the Canadian company other than the name. In the comparison on which this cluster is based, no pharmacy entry carries such a name, so every occurrence of the word Aurora in the Polish list today denotes the manufacturer. This is a conclusion drawn from the data, not an assumption made for convenience.

However, the same trap is listed under a different word. Sirius appears twice: raz jako pozycja S-LAB, raz jako Tilray Sirius, where the Tilray component belongs to the commercial name of the strain and is not an added designation of the entity. The tool that removes the company name from the label must have a clear list of such exceptions, as it cannot be determined from the text alone.

There is a second layer of misunderstanding. The registered name of the Aurora entry does not contain the strain name at all: it carries the designation of the entity, the declared content of active substances, and a directly stated margin of ten percent in either direction. The commercial name like Delahaze or Ghost Train Haze is only added in parentheses by the pharmacy database. Therefore, the patient reads two naming systems simultaneously, and it is these, not the plant itself, that are the source of most errors.

What distinguishes Aurora's raw material from that of other manufacturers?

Formally, nothing. Like others, Aurora provides pharmaceutical raw material dispensed by a doctor's prescription in the Rpw category, with declared content and an entered margin of deviation. Differences only become apparent in the list: eight out of ten names do not have a second supplier with us, and one entry is described differently than its namesakes.

That one entry is Pink Kush. Under this name, there are eight registration entries in pharmacies from five manufacturers, and the list assigns nerolidol as the leading terpene to seven of them. Aurora's entries assign myrcene. The trade name is the same, but the profile description is not, and the list does not indicate whether a different phenotype, a different batch, or just a different laboratory is involved. The difference is verifiable in the data, and it is this that distinguishes this raw material, not a declaration of quality.

The company describes the process and standardization itself, and these sentences should be read accordingly. The Polish version of its website states that production meets EU-GMP standards, cultivation follows GACP principles, and testing includes purity, potency, and active ingredient content. These are the manufacturer's statements, not the result of independent control: none of them has a certificate number or batch document, and the subpages dedicated to production, which are linked from search results, today redirect to the homepage.

However, the registry entry itself is verifiable. It establishes the dispensing category, the form of the raw material, and the permissible deviation from the declared values, and it is this, not promotional material, that defines the limits of what a pharmacy can dispense from such packaging.

What is known and what is not known about the raw material from this producer?

From the documentation, we know as much as the registry entry states: dispensing category, form of the raw material, declared content, and permissible deviation. The rest comes from descriptive databases and the company's material. No clinical study for this manufacturer's raw material as such has been published, and no one publicly shares analysis certificates for individual batches.

The state of the description of these ten strains can be quantified. Five of them are described by two Polish profile databases simultaneously, and in each of these five cases, the lists of aromatic compounds diverge. For Farm Gas and Black Jelly, the sources agree exactly on one compound, while the rest is mentioned by only one of them. The remaining five are described by one source, so there is nothing to compare them with. For four names, the descriptions do not even agree on whether the entry is an indica, sativa, or hybrid.

We do not provide percentage shares for aromatic compounds, and this is due to measurement, not caution. The profile database has twelve records for this manufacturer's entry. We summed the provided shares in each of them: the lowest total is sixty-one, the highest ninety-one, and the median seventy-nine. No record reaches one hundred, so there are missing points from nine to thirty-nine, about which the source says nothing. The percentage, for which no one signed the basis of calculation, reads in the drug description like the result of a laboratory measurement, although it is not, and that is why we leave only the composition.

This same database shows two more things. Electric Honeydew has two separate registration entries with this manufacturer with different declared strengths, and the aromatic profile has been copied identically regarding the unit. Pink Kush has the opposite: two records with the same registration designation, one current and one marked as withdrawn, and the lists of compounds in them differ. Patient reports circulating on forums describe individual packages without a comparative group and without knowledge of the dose, so they are experiences, not evidence for the raw material as a whole.

What adverse effects have been reported after using Aurora's raw material?

Separately, none. There is no public compilation that would attribute reports to the raw material of this manufacturer, as safety oversight is conducted for the packaging with the serial number, not for the company's label. The name Aurora is not a unit that can be counted in this system, and the number of its entries in the list does not change that.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

A report regarding a batch purchased under the label of this manufacturer is directed where any other report goes: to the attending physician or to the pharmacist, and formally to the registration office, always with the serial number from the packaging. This number is the only data linking the symptom to a specific raw material. The strain name alone is not sufficient, as seen above, it can encompass several registration entries with different descriptions.

How does the availability of Aurora products change in pharmacies?

Unevenly and without warning. The entry in the register includes the position of a specific entity, and whether the dried flower is on the shelf depends on the batch that has just passed release and reached the wholesaler. Therefore, a name present in the list can go weeks without being available in any pharmacy in the country.

This is evident in the descriptive data itself. One of the two Pink Kush entries from this manufacturer is marked as withdrawn in the profile database, although the registration name remains the same, and for Electric Honeydew, two entries with different declared strengths have different availability assigned. Thus, the list of strains and the list of what can be purchased in a specific week are two different sets and should not be confused.

The current state of the shelf is known only to the pharmacy filling the prescription, as the wholesaler changes it from day to day. The compilation of names that are allowed to be there today has been gathered by a review of available strains. A separate issue is the very word dried flower: a pharmacy item from the Rpw category and products from of the dried flower category are subject to completely different regulations, although they end up on the same list in the search engine.

Frequently asked questions about Aurora's raw material

Does Aurora grow hemp in Poland?

No. It is listed in the Polish register as the entity responsible for the raw material, not as a producer conducting cultivation by the Vistula River. The parent company is Canadian, the entity on the label is German, and the country of origin of a specific batch is not provided in the public record.

How many strains of Aurora are in Polish pharmacies?

Ten names in a compilation covering eighty-five cultivars. This places it fifth among sixteen manufacturers present in this market, behind S-LAB, Tilray, Synoptis Pharma, and Canopy Growth.

Is Aurora Indica a strain from this manufacturer?

No. Aurora Indica is a cultivar developed by Nirvana Seeds from a combination of Afghani and Northern Lights strains and is not connected to the Canadian company except by name. In the list on which we base this text, there is actually no pharmacy item with that name.

Why is the strain name not in the registration name?

Because the registration name describes the raw material by the responsible entity and the declared content with a margin of deviation, not by cultivar. The trade name like Delahaze is only added in parentheses by the pharmacy database, outside the register.

Does Aurora provide research results for its batches?

We did not find such documents. The Polish website of the company describes production standards and the scope of research, but does not publish analysis certificates for individual series, and its production subpages currently redirect to the main page.

Which strains of Aurora have competition in pharmacies?

Two. Pink Kush is listed in eight registration entries from five manufacturers, and Ghost Train Haze in two, from Aurora and S-LAB. The remaining eight names have no second supplier.

Hemp dried flower is a pharmaceutical raw material dispensed by prescription in the Rpw category. The material is informational in nature and does not replace consultations with the attending physician or advice from a pharmacist.

Editorial text: redakcja ubucha.pl.